R1	Has_negation Arg1:T3 Arg2:T2	
*	OR T4 T5 T6
R2	Subsumes Arg1:T3 Arg2:T4	
R3	AND Arg1:T1 Arg2:T3	
*	OR T11 T12
R4	Has_temporal Arg1:T11 Arg2:T10	
R5	Has_qualifier Arg1:T11 Arg2:T9	
R6	AND Arg1:T15 Arg2:T16	
R7	Subsumes Arg1:T19 Arg2:T20	
*	OR T17 T21 T22 T18 T24 T19
R8	Has_temporal Arg1:T15 Arg2:T25	
R9	Subsumes Arg1:T15 Arg2:T17	
R10	Has_negation Arg1:T28 Arg2:T29	
R11	AND Arg1:T27 Arg2:T28	
R12	Has_mood Arg1:T32 Arg2:T31	
*	OR T34 T35
R13	AND Arg1:T37 Arg2:T38	
T1	Condition 18 27	psoriasis
T2	Negation 28 38	other than
T3	Condition 39 63	chronic plaque psoriasis
T4	Qualifier 70 77	guttate
T5	Qualifier 79 92	erythrodermic
T6	Qualifier 94 102	pustular
T9	Qualifier 124 130	active
T10	Temporal 132 139	ongoing
T11	Condition 140 153	skin diseases
T12	Condition 157 172	skin infections
T13	Non-representable 182 229	interfere with examination of psoriasis lesions
T15	Procedure 262 271	treatment
T16	Condition 252 261	psoriasis
T17	Drug 301 308;321 336	topical corticosteroids
T18	Drug 312 336	systemic corticosteroids
T19	Drug 344 363	topical medications
T20	Drug 370 378	coal tar
T21	Drug 381 385;398 409	oral medications
T22	Drug 389 409	biologic medications
T24	Procedure 446 456	UV therapy
T23	Non-representable 458 642	The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
T25	Temporal 231 238	Ongoing
T27	Procedure 651 672	oral estrogen therapy
T28	Drug 684 708	oral contraceptive pills
T29	Negation 674 683	excluding
T30	Pregnancy_considerations 710 837	Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.
T31	Mood 848 857	unwilling
T32	Procedure 861 887	limit exposure to UV light
T33	Non-query-able 889 1012	Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk
T34	Condition 1028 1059	disorders of calcium metabolism
T35	Condition 1067 1080	hypercalcemia
T36	Competing_trial 1082 1233	Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
T37	Condition 1246 1253	allergy
T38	Drug 1257 1280	any component of the IP
